Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Relatlimab |
Synonyms | |
Therapy Description |
Relatlimab (BMS-986016) is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 9520-9520). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Relatlimab | BMS-986016 | Immune Checkpoint Inhibitor 149 LAG3 Antibody 18 | Relatlimab (BMS-986016) is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 9520-9520). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03743766 | Phase II | Relatlimab Nivolumab + Relatlimab Nivolumab | Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | Completed | USA | 0 |
NCT02658981 | Phase I | Relatlimab Urelumab Nivolumab + Urelumab Nivolumab + Relatlimab | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | Completed | USA | 0 |
NCT04150965 | Phase Ib/II | Relatlimab BMS-986207 BMS-986207 + Dexamethasone + Pomalidomide Dexamethasone + Pomalidomide + Relatlimab Dexamethasone + Elotuzumab + Pomalidomide | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | Active, not recruiting | USA | 0 |
NCT02061761 | Phase Ib/II | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | Completed | USA | CAN | 0 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Active, not recruiting | USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | AUT | AUS | 1 |